

ASX Announcement ([ASX: AXE](#))

28 August 2025

Archer progresses its ^{12}CQ quantum project and Biochip

FY25 results and Appendix 4E.

Key Highlights

^{12}CQ quantum project

- Improved control capabilities by demonstrating the Coulomb blockade phenomenon at room temperature. Partnering with an international research partner to improve control over electrons.
- Designed and fabricated a new resonator circuit. This achieved strong coupling between the spin states of Archer's proprietary carbon-based spin material and the superconducting resonator, moving the company closer to achieving a functional qubit.
- Increased spin coherence times at room temperature for its novel ^{12}CQ chip qubit film material from approximately 385 nanoseconds to around 800 nanoseconds under certain conditions.
- Created two proof-of-concept superconducting circuits containing up to eight resonators each to bolster readout.

TMR sensors

- Commenced identifying opportunities for TMR sensor use in industries such as artificial intelligence, automotive systems, internet-of-things devices, and data centres. Utilising the team's quantum expertise to identify development opportunities, Archer has already received prototype sensors from its foundry partner.

Biochip

- Integrated Archer's proprietary biosensor technology with CMOS readout circuitry.
- Entered partnerships with leading research to improve the testing performance of blood on the biosensor and develop an integrated potassium testing cartridge.
- Fabricated a miniaturised biosensor chip design to improve scalability and reduce cost.
- Built on biosensor feasibility work in sensing potassium by developing a conditioning protocol that improved test-to-test repeatability by as much as 10 times.

Corporate

- Appointment of Dr Simon Ruffell as Chief Executive Officer in March 2025 which demonstrated the strong progress Archer made in 2025 and its ambitions for the future.

For personal use only

- Establishment of a highly credentialed Advisory Committee to provide advice to the Archer board on strategy and the commercialisation of the company's projects
- Continued implementation of an updated corporate strategy that accelerates the commercialisation roadmap of Archer's technologies.
- Cash position of \$13.7 million and no debt to fund R&D and activities for further technology development and commercialisation of the product suite.

Archer Materials Limited ("Archer", the "Company", "ASX: AXE"), a semiconductor company advancing the quantum technology and medical diagnostics industries, provides its results and Appendix 4E for the twelve months ended 30 June 2025 ("full year").

Commenting on FY25 activities, Greg English, Executive Chairman of Archer, said:

"Over the past year, Archer has made significant strides in advancing both its ¹²CQ quantum computing and Biochip platforms.

"The quantum team achieved meaningful technical milestones for developing readout and control capabilities of the quantum device. This includes demonstrating Coulomb blockade, improving spin coherence times, and integrating quantum materials with superconducting circuits, all while pursuing commercial opportunities for the TMR sensor technology.

"Simultaneously, Archer's Biochip team has seen critical developments, including identifying its first use case in chronic kidney disease, successful CMOS integration, biosensor enhancements, and bolstering the future potential scalability of the biosensor.

"These accomplishments, as well as the appointment of new CEO, Dr Simon Ruffell and the Advisory Committee, are the result of Archer's commitment to innovation, global collaboration, and execution of its commercialisation strategy, supported by a robust financial position."

The Board of Archer authorised this announcement to be given to ASX.

Investor enquiries

Howard Marks
+61 402 438 019

howard.marks@automicgroup.com.au

Media enquiries

Dylan Mark
+61 475 783 675

dylan.mark@automicgroup.com.au

About Archer

Archer is a technology company that operates within the semiconductor industry. The Company is developing advanced semiconductor devices, including chips relevant to quantum computing, sensing, and medical diagnostics. Archer utilises its global partnerships to develop these technologies for potential deployment and use across multiple industries.
www.archerx.com.au

1. Company Details

Name of entity:	Archer Materials Limited
ABN:	64 123 993 233
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

	30 June 2025 \$	30 June 2024 \$	Variance \$	Variance %
Revenue from ordinary activities	-	-	-	-
Profit/(loss) from ordinary activities after tax attributable to members	(6,972,006)	(4,803,150)	(2,168,856)	45%
Net profit/(loss) for the period attributable to members	(6,972,006)	(4,803,150)	(2,168,856)	45%

Dividends

No dividends have been paid or proposed during the current reporting period.

Key notes

The net loss of the Group for the year ended 30 June 2025 was \$6,972,006 (2024: \$4,803,150) and includes:

- Share based payments expense of \$1,889,842 representing the expense associated with unlisted option vesting during the year (2024: \$603,093) net of forfeitures.
- Direct expenditure on quantum and biochip technology research activities (including allocation of direct personnel costs) of \$4,791,577 (2024: \$4,524,190).
- Unrealised gains and losses associated with the fair value adjustment of Archer's share and option investments in:
 - Volatus Capital Corp (shares) as at 30 June 2025 gain of \$64,148 (2024: loss of \$9,665); and
 - ChemX Materials Limited (shares and options) as at 30 June 2025 loss of \$519,375 (2024: loss of \$297,955).

The above expense items are offset by:

- An income amount of \$2,055,447, being the estimated research and development tax incentive receivable based on associated expenditure for the year ended 30 June 2025, adjusted for actual amounts received the prior year tax incentive claimed (30 June 2024: \$2,135,936); and
- Interest income of \$743,288 (2024: \$941,147).

3. Net tangible assets

	30 June 2025 (cents)	30 June 2024 (cents)	Variance (cents)	Variance
Net tangible assets per share	6.30 cents	8.31 cents	(2.01) cents	(24%)

The net tangible assets calculation does not include rights-of-use assets of \$14,973 (30 June 2024: \$109,309) or intangible assets of \$669,227 (30 June 2024: \$502,754) but includes the lease liabilities of \$14,974 (30 June 2024: \$109,309).

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

No dividends have been paid or proposed during the current or prior reporting period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The Financial Statements and accompanying notes for the Group for the year ended 30 June 2025, contained in the attached Annual Report, upon which this Appendix 4E is based, have been audited by Grant Thornton Audit Pty Ltd. An unmodified audit report has been provided.

11. Attachments

Details of attachments (if any):

The Annual Report, which includes Financial Statements and accompanying notes for the Group for the year ended 30 June 2025 is attached.

12. Signed

As authorised by the Board of Directors

Signed



Date

28 August 2025

Greg English
Executive Chairman
Adelaide

For personal use only